source
- Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectationsBiogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.BioSpace · 5h ago↗ source
- Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitorA biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse mergers to take their experimental medicines ont…Endpoints · 5h ago↗ source
- STAT+: Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicatedIn this edition of AI Prognosis: A conversation about benchmarking leading clinical chatbots, investor view on AI in biopharma, and more.